Xalacom clinical trials
How each study uses Xalacom is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Xalacom
- 10
Studies by the year they started
10 studies that test it; most in 2005 (4)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 3
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (6) · Ophthalmic Consultants Centres, Canada (1) · Aristotle University Of Thessaloniki (1) · University of Campinas, Brazil (1) · Pfizer (1)
Often tested with
Tested in the same studies.
Latanoprost (3) · Timolol (2) · Dorzolamide-timolol combination (1) · Duotrav (1) · Ganfort (1)
Studies
Open first, then newest update. How each study uses Xalacom is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).CompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00383019Written as XalacomHow we know
- Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.CompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00143208Written as XalacomHow we know
- A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With GlaucomaCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00159653Written as XalacomHow we know
- Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular HypertensionCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00219596Written as XalacomHow we know
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ GlaucomaCompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00140049Written as XalacomHow we know
- A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With GlaucomaCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00277498Written as XalacomHow we know
- A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle GlaucomaCompletedPhase 4Ophthalmic Consultants Centres, CanadaNCT00887029Written as Xalacom (latanoprost-timolol ophthalmic drops)How we know
- Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination TherapyCompletedPhase 4Aristotle University Of ThessalonikiNCT01779284Written as Latanoprost/Timolol therapyHow we know
- Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAGCompletedPhase 4University of Campinas, BrazilNCT01978015Written as latanoprost and maleate timolol fixed combinationHow we know
- A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular HypertensionCompletedPhase 3PfizerNCT00150267Written as XalacomHow we know